CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research note released on Saturday.

Several other equities analysts have also recently commented on the stock. Truist Financial raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Monday, April 20th. Evercore reissued an “outperform” rating and issued a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Morgan Stanley restated an “underweight” rating and set a $33.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $65.94.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $54.83 on Friday. CRISPR Therapeutics has a 52-week low of $34.87 and a 52-week high of $78.48. The stock’s 50-day simple moving average is $52.34 and its 200 day simple moving average is $54.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 13.32 and a current ratio of 17.97. The stock has a market capitalization of $5.29 billion, a price-to-earnings ratio of -8.82 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The company had revenue of $1.46 million for the quarter. Research analysts forecast that CRISPR Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the transaction, the chief executive officer owned 255,501 shares of the company’s stock, valued at $11,952,336.78. The trade was a 3.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 3,182 shares of the firm’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total transaction of $148,853.96. Following the sale, the general counsel owned 94,308 shares in the company, valued at approximately $4,411,728.24. This trade represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 51,828 shares of company stock worth $2,578,097 over the last three months. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in CRISPR Therapeutics by 98.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after buying an additional 294,222 shares during the last quarter. Nwam LLC grew its position in CRISPR Therapeutics by 455.7% during the third quarter. Nwam LLC now owns 101,769 shares of the company’s stock valued at $6,770,000 after acquiring an additional 83,454 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in CRISPR Therapeutics by 44.7% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 283,111 shares of the company’s stock valued at $18,348,000 after acquiring an additional 87,509 shares during the last quarter. O Neil Global Advisors Inc. purchased a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $10,934,000. Finally, UBS Group AG raised its stake in shares of CRISPR Therapeutics by 7.7% during the fourth quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock worth $132,366,000 after acquiring an additional 180,580 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: HC Wainwright and Brookline Capital Markets both raised several near-term earnings estimates for CRSP, signaling slightly better expectations for 2026 and 2027 profitability. Those revisions can help support the stock by suggesting improving fundamentals. Analyst estimate updates for CRISPR Therapeutics
• Positive Sentiment: Piper Sandler reiterated a Buy view on CRSP, adding to the constructive analyst tone around the name. Piper Sandler Buy rating article
• Neutral Sentiment: CRISPR Therapeutics was also listed as a “trending stock” on Zacks, which reflects elevated investor interest but does not by itself change the company’s outlook. CRISPR Therapeutics trending stock article
• Neutral Sentiment: One note highlighted conflicting analyst sentiment across healthcare names, reinforcing that CRSP is still viewed as a high-uncertainty biotech story rather than a clear fundamentals-driven winner. Conflicting analyst sentiment article
• Negative Sentiment: Despite some upgrades, the company is still expected to post meaningful losses in the coming years, and Brookline cut its FY2026 and FY2030 earnings outlook in some areas, reminding investors that CRSP remains a speculative, pre-profitability story. CRISPR Therapeutics earnings estimate updates

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.